Biocon Biologics Debuts on the ASIA IP ELITE 2019 List
Bengaluru, Karnataka, India, November 12, 2019:
Biocon Ltd, an innovation-led global biopharmaceuticals company, today announced that it has been recognised as the ASIA IP ELITE for the fourth year in a row and its wholly-owned subsidiary Biocon Biologics makes its debut on this prestigious list in 2019 by the IP Business Congress Asia (IPBC Asia) for robust Intellectual Property (IP) management and consistent IP value creation.
In 2016, Biocon became the first and only Indian pharmaceutical company to be featured on the prestigious ASIA IP ELITE list. This year its subsidiary Biocon Biologics, a fully integrated ‘pure play’ global biosimilars company, dedicated to developing high quality, affordable biosimilars for patients globally, has made it to the ASIA IP ELITE 2019 list, reinforcing Biocon’s commitment towards creating intellectual wealth and value for its stakeholders. Biocon Biologics received this Award at the recently concluded IP Business Congress Asia in Tokyo, Japan.
Dr. Christiane Hamacher, Chief Executive Officer, Biocon Biologics, said: “We are pleased that Biocon Biologics has been inducted into the Asia IP ELITE 2019 List. This recognition is an endorsement of Biocon Group’s strategy of value creation through innovation and IP to serve patient needs across the world. Biocon Biologics has a strong portfolio of Intellectual Property assets with granted patents and trademarks. Our IP team has demonstrated a sustained commitment to building best-in-class in-house IP function focussed on continuous excellence in IP value creation.”
Biocon Biologics has a product pipeline of 28 molecules, including 11 partnered with Mylan, several with Sandoz, and many being developed independently. The company’s therapeutic basket includes molecules from diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases.
The companies selected as the Asia IP Elite 2019 were honoured at the latest edition of the IP Business Congress Asia, which is hosted by Intellectual Asset Management, the publishers of the world’s leading IP magazine IAM.
About Biocon Biologics:
Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company. Biocon Biologics is engaged in developing high quality, affordable biosimilars aimed at expanding patient access to cutting-edge class of therapies across the world. It is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization globally. Biocon Biologics aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in developed markets like EU, Australia, U.S. and Japan. Biocon Biologics has a product pipeline of 28 molecules, including 11 partnered with Mylan, several with Sandoz and many being developed independently.
About Biocon Ltd:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It is a leading global player for APIs including statins, immunosuppressants and specialty molecules. Biocon has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the U.S. and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Biocon is committed to pursue the path of innovation to develop products that have the potential to benefit a billion lives. Biocon Biologics is a subsidiary of Biocon Ltd. It is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in developed markets like EU, Australia, U.S. and Japan.
Download Press Release